Interaction of levofloxacin with lung surfactant at the air-water interface
Source abstract
Abstract
The molecular-level interaction of levofloxacin with lung surfactant was investigated using Langmuir monolayers and atomistic molecular dynamics (MD) simulations. In the simulation, the DPPC/POPC mixed monolayer was used as a lung surfactant model and the molecules of levofloxacin were placed at the air-lipid interface to mimic the adsorption process on the lung surfactant model. The simulation results indicate that amphoteric levofloxacin expands the lung surfactant, also stabilizing the film for levofloxacin fractions until 10% w/w at least. The Langmuir monolayers made with the lung surfactant Curosurf had expanded isotherms upon incorporation of levofloxacin, without changes in monolayer elasticity. In fact, levofloxacin induced film stability with increased collapse pressures in the Curosurf isotherms and delayed the phase transition, according to Brewster angle microscopy (BAM) imaging. Using polarization-modulated infrared reflection-absorption spectroscopy (PM-IRRAS), we found that levofloxacin is preferentially located in the head group region, inducing an increased organization of the Curosurf film. This location of levofloxacin was confirmed with MD simulations. The stability inferred demonstrates that the lung surfactant can be used as a drug delivery system for the administration via inhalation or intratracheal instillation of levofloxacin to treat lung diseases such as pneumonia and respiratory distress syndrome.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Lipid Membrane Structure and Behavior · Electrostatics and Colloid Interactions · Inhalation and Respiratory Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (54)
Show source-provided references
1. Levofloxacin: a review of its antibacterial activity: pharmacokinetics and therapeutic efficacy10.2165/00003495-199447040-00008 ↗
2. A critical review of the fluoroquinolones: focus on respiratory tract infections10.2165/00003495-200262010-00002 ↗
3. 19th WHO Model List of Essential Medicines (April 2015). WHO. April 2015. Retrieved September 17, 2016.
4. Barrier or carrier? Pulmonary surfactant and drug delivery10.1016/j.ejpb.2015.02.014 ↗
5. Pulmonary surfactant in health and human lung diseases: state of the art10.1183/09031936.99.13614779 ↗
6. Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs10.1164/ajrccm/144.4.909 ↗
7. Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae10.1111/j.1476-5381.1996.tb16016.x ↗
8. Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity10.1111/j.1476-5381.1996.tb15442.x ↗
9. Surfactant versus saline as a vehicle for corticosteroid delivery to the lungs of ventilated rabbits10.1203/00006450-199804000-00018 ↗
10. Combined treatment with surfactant and specific immunoglobulin reduces bacterial proliferation in experimental neonatal group B streptococcal pneumonia10.1164/ajrccm.159.6.9810047 ↗
11. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study10.1542/peds.2007-1973 ↗
12. Antimicrobial and biophysical properties of surfactant supplemented with an antimicrobial peptide for treatment of bacterial pneumonia10.1128/AAC.04937-14 ↗
13. Surfactant therapy and antibiotics in neonates with meconium aspiration syndrome: a systematic review and meta-analysis10.1038/jp.2016.32 ↗
14. Interaction of gentamicin with phosphatidylserine/phosphatidylcholine mixtures in adsorption monolayers and thin liquid films: morphology and thermodynamic properties10.1007/s00249-010-0583-1 ↗
15. Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes10.1016/j.ijantimicag.2014.07.023 ↗
16. Effect of tetracycline antibiotic on the monolayers of phosphatidylcholines at the air-water interface10.1016/j.colsurfa.2015.05.055 ↗
17. Effect of antitubercular drugs on dipalmitoylphosphatidylcholine monolayers: implications for drug loaded surfactants10.1016/j.resp.2004.10.003 ↗
18. Lung surfactant dysfunction in tuberculosis: effect of mycobacterial tubercular lipids on dipalmitoylphosphatidylcholine surface activity10.1016/j.colsurfb.2005.08.014 ↗
19. Effect of mycobacterial lipids on surface properties of Curosurf: implications for lung surfactant dysfunction in tuberculosis10.1016/j.resp.2008.04.004 ↗
20. Interplay of mycolic acids: antimycobacterial compounds and pulmonary surfactant membrane: a biophysical approach to disease10.1016/j.bbamem.2012.09.015 ↗
21. Effects of a novel antimycobacterial compound on the biophysical properties of a pulmonary surfactant model membrane10.1016/j.ijpharm.2013.03.062 ↗
22. Surfactant supplemented with an antimicrobial peptide for the treatment of bacterial pneumonia: antimicrobial and biophysical properties10.1128/AAC.04937-14 ↗
23. Interaction of the macrolide antibiotic azithromycin with lipid bilayers: effect on membrane organization fluidity, and permeability10.1007/s11095-004-1885-8 ↗
24. Interactions of ciprofloxacin with DPPC and DPPG: fluorescence anisotropy: ATR-FTIR and 31P NMR spectroscopies and conformational analysis10.1016/j.bbamem.2008.08.015 ↗
25. Molecular dynamics of dibenz[a,h]anthracene and its metabolite interacting with lung surfactant phospholipid bilayers10.1039/C5CP01443C ↗
26. Quantitative treatment of surface potentials in Langmuir films from aromatic amphiphiles10.1016/S0009-2614(01)00175-0 ↗
27. Langmuir films and mechanical properties of polyethyleneglycol fatty acid esters at the air-water interface10.1016/j.colsurfa.2016.03.032 ↗
28. Efficient molecular packing of glycerol monostearate in Langmuir monolayers at the air-water interface10.1016/j.colsurfa.2016.08.016 ↗
29. The negligible effects of the antifungal natamycin on cholesterol-dipalmitoylphosphatidylcholine monolayers may explain its low oral and topical toxicity for mammals10.1016/j.colsurfb.2014.06.058 ↗
30. GROMACS 4 algorithms forhighly efficient, load-balanced, and scalable molecular simulation10.1021/ct700301q ↗
31. A biomolecular forcefield based on the free enthalpy of hydration and solvation: the GROMOSforce-field parameter sets 53A5 and 53A610.1002/jcc.20090 ↗
32. An automated force field topology builder (ATB) and repository: version 1.010.1021/ct200196m ↗
33. Lipid models for united-atom molecular dynamics simulations of proteins10.1021/ct8003468 ↗
34. The missing term in effective pair potentials10.1021/j100308a038 ↗
35. A computational investigation of thermodynamics, structure, dynamics and solvation behavior in modified water models10.1063/1.2841127 ↗
36. Surface tension of the most popular models of water by using the test-area simulation method10.1063/1.2715577 ↗
37. CELLmicrocosmos 2.2 MembraneEditor: a modular interactiveshape-Based software approach to solve heterogeneous membrane packing problems10.1021/ci1003619 ↗
38. Quiet high-resolution computer models of a plasma10.1016/0021-9991(74)90010-2 ↗
39. Canonical sampling through velocity rescaling10.1063/1.2408420 ↗
40. Molecular dynamics with coupling to an external bath10.1063/1.448118 ↗
41. Particle mesh Ewald: an Nlog(N) method for Ewald sums in large systems10.1063/1.464397 ↗
42. LINCS. A linear constraint solver for molecular simulations10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H ↗
43. Pulmonary surfactant: surface properties and function of alveolar and airway surfactant10.1351/pac199264111745 ↗
44. The role of lipids in pulmonary surfactant10.1016/S0925-4439(98)00061-1 ↗
45. Surface activity in situ in vivo, and in the captive bubble surfactometer10.1016/S1095-6433(01)00316-6 ↗
46. Comparative pharmacodynamic interaction analysis between ciprofloxacin: moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus10.1093/jac/dkn473 ↗
47. Molecular dynamics simulation of phase transitions in model lung surfactant monolayers10.1016/j.bbamem.2011.06.026 ↗
48. Challenges in analysing and visualizing large-scale molecular dynamics simulations: domain and defect formation in lung surfactant monolayers10.1088/1742-6596/385/1/012002 ↗
49. Molecular view of phase coexistence in lipid monolayers10.1021/ja304792p ↗
50. The mechanism of collapse of heterogeneous lipid monolayers10.1016/j.bpj.2014.05.053 ↗
51. Oxidized aromatic-aliphatic mixed films at the air-aqueous solution interface10.1021/jp402737n ↗
52. Prednisolone adsorption on lung surfactant models: insights on the formation of nanoaggregates, monolayer collapse and prednisolone spreading10.1039/C6RA28422A ↗
53. Thermodynamic and infrared analyses of the interaction of chlorpromazine with phospholipid monolayers10.1021/jp0633143 ↗
54. Modeling lung surfactant interactions with benzo[a]pyrene10.1002/chem.201605945 ↗